

**Clinical Policy: Rimegepant (Nurtec ODT)**

Reference Number: CP.PHAR.490

Effective Date: 09.01.20

Last Review Date: 08.21

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Rimegepant (Nurtec<sup>®</sup> [orally disintegrating tablet] ODT) is a calcitonin gene-related peptide receptor (CGRP) antagonist.

**FDA Approved Indication(s)**

Nurtec ODT is indicated for the:

- Acute treatment of migraine with or without aura in adults
- Preventive treatment of episodic migraine in adults.

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Nurtec ODT is **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria****A. Acute Migraine Treatment (must meet all):**

1. Diagnosis of migraine headache;
2. Age  $\geq$  18 years;
3. Failure of at least TWO formulary 5HT<sub>1B/1D</sub>-agonist migraine medications\* (e.g., sumatriptan, rizatriptan, zolmitriptan) at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated;  
*\*Prior authorization may be required.*
4. For dose increase requests to quantities > 1 box of 8 ODTs per month, member must meet criteria in *Section I, B* below for migraine prophylaxis;
5. Nurtec ODT is not prescribed concurrently with other CGRP inhibitors (e.g., Aimovig<sup>®</sup>, Ajovy<sup>®</sup>, Emgality<sup>®</sup>, Ubrelvy<sup>®</sup>, Vyepti<sup>™</sup>);
6. Dose does not exceed 75 mg (1 ODT) per day (one blister pack per month).

**Approval duration: 6 months****B. Migraine Prophylaxis (must meet all):**

1. Diagnosis of episodic migraine;
2. Member experiences  $\geq$  4 migraine days per month for at least 3 months;
3. Member does not have chronic migraine, defined as  $\geq$  15 headache days/month with  $\geq$  8 migraine days/month for at least 3 months;
4. Prescribed by or in consultation with a neurologist, headache, or pain specialist;

5. Age  $\geq$  18 years;
  6. Failure of at least 2 of the following oral migraine preventative therapies, each for 8 weeks and from different therapeutic classes, unless clinically significant adverse effects are experienced or all are contraindicated: antiepileptic drugs (e.g., divalproex sodium, sodium valproate, topiramate), beta-blockers (e.g., metoprolol, propranolol, timolol), antidepressants (e.g., amitriptyline, venlafaxine);
  7. Nurtec ODT is not prescribed concurrently with Botox<sup>®</sup> or other CGRP inhibitors (e.g., Aimovig, Ajovy, Emgality, Ubrelvy, Vyepti);
  8. Dose does not exceed 75 mg (1 ODT) every other day (two blister packs per month).
- Approval duration: 3 months**

**C. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Acute Migraine Treatment (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. For dose increase requests to quantities  $>$  1 box of 8 ODTs per month, member must meet criteria in *Section I, B* above for migraine prophylaxis;
4. Nurtec ODT is not prescribed concurrently with other CGRP inhibitors (e.g., Aimovig, Ajovy, Emgality, Ubrelvy, Vyepti);\*  
*\*This requirement does not apply to CA if member was previously approved via Centene benefit and is currently stable on therapy with both oral and injectable CGRP inhibitors*
5. If request is for a dose increase, new dose does not exceed 75 mg (1 ODT) per day (one blister pack per month)

**Approval duration: 12 months**

**B. Migraine Prophylaxis (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member has experienced and maintained positive response to therapy as evidenced by a reduction in migraine days per month from baseline;
3. Nurtec ODT is not prescribed concurrently with Botox<sup>®</sup> or other CGRP inhibitors (e.g., Aimovig, Ajovy, Emgality, Ubrelvy, Vyepti);\*  
*\*This requirement does not apply to CA if member was previously approved via Centene benefit and is currently stable on therapy with both oral and injectable CGRP inhibitors*
4. If request is for a dose increase, new dose does not exceed 75 mg (1 ODT) every other day (two blister packs per month).

**Approval duration: 6 months**

**C. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 12 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

5-HT: serotonin	CGRP: calcitonin gene-related peptide
AAN: American Academy of Neurology	FDA: Food and Drug Administration
AHS: American Headache Society	ODT: orally disintegrating tablet

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Abortive Migraine Therapy		
Drug Name	Dosing Regimen	Dose Limit/Maximum Dose
<b><i>Triptans</i></b>		
naratriptan (Amerge <sup>®</sup> )	One tablet (1 or 2.5 mg) PO at onset; can be repeated in 4 hours	5 mg/day
almotriptan (Axert <sup>®</sup> )	6.25 to 12.5 mg PO QD May repeat dose in 2 hours	25 mg/day
frovatriptan (Frova <sup>®</sup> )	2.5 mg PO QD May repeat dose in 2 hours	7.5 mg/day
sumatriptan (Imitrex <sup>®</sup> nasal spray)	One spray (5 to 20 mg) at onset into one nostril; can be repeated in 2 hours	40 mg/day
sumatriptan (Imitrex <sup>®</sup> )	One tablet (25 to 100 mg) PO at onset; can be repeated in two hours	200 mg/day
rizatriptan (Maxalt <sup>®</sup> /Maxalt MLT <sup>®</sup> )	One tablet (5 or 10 mg) PO at onset of migraine headache; can be repeated in two hours	30 mg/day
eletriptan (Relpax <sup>®</sup> )	20 or 40 mg PO QD May repeat dose in 2 hours	40 mg/dose 80 mg/day

Abortive Migraine Therapy		
Drug Name	Dosing Regimen	Dose Limit/Maximum Dose
zolmitriptan (Zomig <sup>®</sup> /Zomig <sup>®</sup> ZMT)	1.25 or 2.5 mg PO QD May repeat dose in 2 hours	5 mg/dose 10 mg/day
Prophylactic Migraine Therapy		
Drug Name	Dosing Regimen	Dose Limit/Maximum Dose
Anticonvulsants such as: divalproex (Depakote <sup>®</sup> ), topiramate (Topamax <sup>®</sup> ), valproate sodium	<b>Migraine Prophylaxis</b> <i>Refer to prescribing information or Micromedex</i>	<i>Refer to prescribing information or Micromedex</i>
Beta-blockers such as: propranolol (Inderal <sup>®</sup> ), metoprolol (Lopressor <sup>®</sup> )*, timolol, atenolol (Tenormin <sup>®</sup> )*, nadolol (Corgard <sup>®</sup> )*	<b>Migraine Prophylaxis</b> <i>Refer to prescribing information or Micromedex</i>	<i>Refer to prescribing information or Micromedex</i>
Antidepressants/tricyclic antidepressants* such as: amitriptyline (Elavil <sup>®</sup> ), venlafaxine (Effexor <sup>®</sup> )	<b>Migraine Prophylaxis</b> <i>Refer to prescribing information or Micromedex</i>	<i>Refer to prescribing information or Micromedex</i>

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): history of hypersensitivity reaction to rimegepant, Nurtec ODT, or to any of its components.
- Boxed warning(s): none reported

*Appendix D: General Information*

The American Headache Society (2018) provides the following migraine guidance:

- Migraine patients who need to use acute treatments on a regular basis should be instructed to limit treatment to an average of 2 headache days per week, and patients observed to be exceeding this limit should be offered preventive treatment.

Indications for preventive treatment:

- Attacks significantly interfere with patients' daily routines despite acute treatment
- Frequent attacks (≥ 4 migraine headache days [per month])
- Contraindication to, failure, or overuse of acute treatments, with overuse defined as:

- 10 or more days per month for ergot derivatives, triptans, opioids, combination analgesics, and a combination of drugs from different classes that are not individually overused
- 15 or more days per month for non-opioid analgesics, acetaminophen, and nonsteroidal antiinflammatory drugs (NSAIDs [including aspirin])
- Adverse effects with acute treatments
- Patient preference
- Prevention should also be considered in the management of certain uncommon migraine subtypes, including hemiplegic migraine, migraine with brainstem aura, migraine with prolonged aura, and those who have previously experienced a migrainous infarction, even if there is low attack frequency.

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
Migraine - acute treatment	75 mg PO as needed. The maximum dose in a 24-hour period is 75 mg. The safety of treating more than 15 migraines in a 30-day period has not been established.	75 mg/day
Migraine prophylaxis	75 mg PO every other day	75 mg/dose

**VI. Product Availability**

ODT (blister pack of 8): 75 mg

**VII. References**

1. Nurtec ODT Prescribing Information. New Haven, CT: Biohaven Pharmaceuticals, Inc.; May 2021. Available at <https://biohaven-nurtec-consumer-assets.s3.amazonaws.com/nurtec-prescribing-information.pdf>. Accessed June 9, 2021.
2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *The Lancet*. August 31, 2019; 394:737-745.
3. MICROMEDEX<sup>®</sup> Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed March 30, 2021.
4. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59:1-18.
5. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012;78:1337-1345.
6. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet* 2021; 397: 51–60.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	04.14.20	08.20

Reviews, Revisions, and Approvals	Date	P&T Approval Date
3Q 2021 annual review: RT4 added new indication for episodic migraine prophylaxis; added clarification in continuation of therapy to indicate requirement for concurrent use with other CGRP inhibitors does not apply to CA if member was previously approved via Centene benefit and is currently stable on therapy with both oral and injectable CGRP inhibitors; replaced HIM.PHAR.21 to reference HIM.PA.154; references reviewed and updated.	06.28.21	08.21

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.